J&J’s run to record highs hasn’t reached the finish line yet. Here are the key drivers
Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares to new highs still has room to run. In a note to clients Wednesday, analysts at UBS raised their price target on the healthcare giant to $320 per share from $280. Their bullish view is based on three factors: (1) Top-line growth inflecting from…
